Incorporation of pazopanib in maintenance therapy of ovarian cancer
Purpose Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor
receptor (VEGFR)-1/-2/-3, platelet-derived growth factor receptor (PDGFR)-α/-β, and c-Kit …
receptor (VEGFR)-1/-2/-3, platelet-derived growth factor receptor (PDGFR)-α/-β, and c-Kit …
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
J Pfisterer, CM Shannon, K Baumann, J Rau… - The Lancet …, 2020 - thelancet.com
Background State-of-the art therapy for recurrent ovarian cancer suitable for platinum-based
re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined …
re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined …
Quality of life predicts outcome of deep brain stimulation in early Parkinson disease
WMM Schuepbach, L Tonder, A Schnitzler, P Krack… - Neurology, 2019 - AAN Enterprises
Objective To investigate predictors for improvement of disease-specific quality of life (QOL)
after deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson disease …
after deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson disease …
Optimal treatment duration of bevacizumab as front-line therapy for advanced ovarian cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 open-label …
J Pfisterer, F Joly, G Kristensen, J Rau… - Journal of Clinical …, 2023 - ingentaconnect.com
PURPOSE To compare standard versus extended duration of bevacizumab treatment in
combination with front-line chemotherapy in women with newly diagnosed stage IIB-IV …
combination with front-line chemotherapy in women with newly diagnosed stage IIB-IV …
Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) …
J Pfisterer, F Joly, G Kristensen, J Rau, S Mahner… - 2021 - ascopubs.org
5501 Background: GOG-0218 established the addition of BEV 15 mg/kg every 3 weeks
(q3w) for 15 months to standard front-line chemotherapy for advanced ovarian cancer, but …
(q3w) for 15 months to standard front-line chemotherapy for advanced ovarian cancer, but …
The contribution of subthalamic nucleus deep brain stimulation to the improvement in motor functions and quality of life
I Tödt, B Al‐Fatly, O Granert, AA Kühn… - Movement …, 2022 - Wiley Online Library
Background Subthalamic nucleus deep brain stimulation (STN‐DBS) effectively treats motor
symptoms and quality of life (QoL) of advanced and fluctuating early Parkinson's disease …
symptoms and quality of life (QoL) of advanced and fluctuating early Parkinson's disease …
Comparing two randomized deep brain stimulation trials for Parkinson's disease
G Deuschl, KA Follett, P Luo, J Rau, FM Weaver… - Journal of …, 2019 - thejns.org
OBJECTIVE Several randomized studies have compared the effect of deep brain stimulation
(DBS) of the subthalamic nucleus with the best medical treatment in large groups of patients …
(DBS) of the subthalamic nucleus with the best medical treatment in large groups of patients …
[HTML][HTML] Interpretation of health-related quality of life outcomes in Parkinson's disease from the EARLYSTIM Study
The EARLYSTIM Study compared deep brain stimulation (DBS) with best medical treatment
(BMT) over 2-years, showing a between-group difference of 8.0 from baseline in favor of …
(BMT) over 2-years, showing a between-group difference of 8.0 from baseline in favor of …
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal …
D Lorusso, F Hilpert, AG Martin, J Rau… - International Journal of …, 2019 - ijgc.bmj.com
Introduction The PENELOPE trial evaluated pertuzumab added to chemotherapy for
biomarker-selected platinum-resistant ovarian cancer. As previously reported, pertuzumab …
biomarker-selected platinum-resistant ovarian cancer. As previously reported, pertuzumab …
AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line …
I Vergote, LC Hanker, A Floquet, J Rau, JW Kim… - 2018 - ascopubs.org
5518 Background: AGO-OVAR 16 study investigated PZ, an oral multi-kinase inhibitor of
VEGFR-1,-2,-3, PDGFR-α and-β and c-Kit. This study was designed to test efficacy, safety …
VEGFR-1,-2,-3, PDGFR-α and-β and c-Kit. This study was designed to test efficacy, safety …